eCF506 is a potent and selective inhibitor of SRC (IC50 < 0.5 nM)eCF506, the first small molecule with subnanomolar IC50 for SRC that requires 3 orders of magnitude greater concentration to inhibit ABL.?

KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

AMG-47a is a potent inhibitor of Lck and T cell proliferation.?AMG-47a could promote the degradation of the KRAS oncoprotein.?AMG-47a selectively reduced the levels of EGFP-KRASG12V protein but did not affect EGFP protein in cells.